氯吡格雷抵抗的研究进展

氯吡格雷可抑制二磷酸腺苷(ADP)与血小板上的受体结合,在几项大型临床试验均显示它可以有效降低动脉内血栓形成事件发生的危险。然而,大约30%患者对氯吡格雷抗血小板聚集效果存在疗效差异性,呈无反应性或半反应性,即"氯吡格雷抵抗"。许多因素在氯吡格雷抵抗的发病机制中起到作用,如:氯吡格雷剂量不足,药物药物的反应,基因多态性等。本文就氯吡格雷的作用机制、氯吡格雷抵抗定义、氯吡格雷抵抗的机制及临床意义等作一综述。

Research Development of Clopidogrel Resistance

Clopidogrel can inhibit the combination of ADP with receptors on platelet.Several clinical trial in large scale have showen that it can effectively decrease the genetic hazard of artery thrombotic events.But about 30% patients have different effect of clopidogrel on the inhibition of platelet aggregation showing no reactivity or half reactivity,which is called clopidogrel resistance.Many factors have their own effects in the pathogenesis of clopidogrel resistance,which includes its underdosage,interaction between drugs,gene polymorphism and so on.This article reviews clopidogrel about its mechanism of action as well as clopidogrel resistance about its definition,pathogenesis ans its clinical significance.